Discover how the MFP refund model will affect pharmacy cash flow and rebate timelines for Medicare Part D drugs in 2026, based on IQVIA’s analysis.

• Financing costs for MFP refunds are lower than the pre-MFP baseline, easing pharmacy cash flow.
• 340B rebate payments are processed faster, resulting in even smaller financing costs.
• This may warrant HRSA reevaluating the condition it imposed to demonstrate the performance of the 340B rebate model before it is expanded beyond the 10 drugs in the rebate pilot.

Download the fact sheet to get actionable insights for pharmacy operations and reimbursement planning.